In vitro actIVity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positIVe and fastidious Gram-negatIVe pathogens

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6053-6063

  Biedenbach, Douglas J ^a   Huband, Michael D ^b,c   Hackel, Meredith ^a   De Jonge, Boudewijn L M ^b   Sahm, Daniel F ^a   Bradford, Patricia A ^b  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; AZD 0914; BACTERIAL DNA; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DNA TOPOISOMERASE IV; ERYTHROMYCIN; GYRASE INHIBITOR; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; BARBITURIC ACID DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); SPIRO COMPOUND; ZOLIFLODACIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; BETA LACTAMASE PRODUCING HAEMOPHILUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS LUGDUNENSIS; STREPTOCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-INFECTIVE AGENTS; BARBITURATES; DNA GYRASE; DNA TOPOISOMERASE IV; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; SPIRO COMPOUNDS;

EID: 84942942868     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01016-15     Document Type: Article

References (31)

1. Ball P. 2001. Future of the quinolones. Semin Respir Infect 16:215-224. http://dx.doi.org/10.1053/srin. 2001.25628.
2. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62:13-59. http://dx.doi.org/10.2165/00003495-200262010-00002.
3. Blondeau JM. 1999. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 43(Suppl B):1-11.
4. Ball P, Mandell L, Niki Y, Tillostson G. 1999. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 21:407-421. http://dx.doi.org/10.2165/00002018-199921050-00005.
5. Rubinstein E. 2001. History of quinolones and their side effects. Chemotherapy 47(Suppl 3):3-8, discussion 44-48.
6. Sousa J, Alves G, Fortuna A, Falcão A. 2014. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf 9:89-105. http://dx.doi.org/10.2174/1574886308666140106154754.
7. Coleman CL, Spencer JC, Chung JO, Reddy P. 2002. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 36:1162-1167. http://dx.doi.org/10.1345/aph.1A414.
8. Lazarczyk DA, Goldstein NS, Gordon SC. 2001. Trovafloxacin hepatotoxicity. Dig Dis Sci 46:925-926. http://dx.doi.org/10.1023/A:1010741510046.
9. Van Bambeke F, Tulkens PM. 2009. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 32:359-378. http://dx.doi.org/10.2165/00002018-200932050-00001.
10. Basarab GS, Brassil P, Doing P, Galullo V, Haimes HB, Kern G, Kutschke A, McNulty J, Schuck VJ, Stone G, Gowravaram M. 2014. Novel DNA gyrase inhibiting spiropyrimidinetriones witha benzisoxazole scaffold: SAR and in vivo characterization. J Med Chem 57:9078-9095. http://dx.doi.org/10.1021/jm501174m.
11. Palmer T. 2014. AZD0914 mode of inhibition, abstr C-1422, p 170. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
12. Sahm DF, Huband MD, de Jonge B. 2014. In vitro activity of AZD0914: a novel spiropyrimidinetrione DNA gyrase inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative bacteria, abstr F-266, p 64. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
13. Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP. 2015. In vitro antibacterial activity of AZD0914: a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59:467-474. http://dx.doi.org/10.1128/AAC.04124-14.
14. Basarab GS, McNulty J, Gales S, Powles-Glover N, Prior H, Lengel D, Jacobsen M, Mueller J. 2014. AZD0914: non-clinical safety profile of a novel gyrase inhibitor for treatment of Neisseria gonorrhoeae infections, abstr F-268, p64. Abstr 54th Intersci Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
15. Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M. 2014. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrugresistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585-5588. http://dx.doi.org/10.1128/AAC.03090-14.
16. Kohlhoff SA, Huband MD, Hammerschlag MR. 2014. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 58:7595-7596. http://dx.doi.org/10.1128/AAC.03920-14.
17. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
19. European Committee on Antimicrobial Susceptibility Testing. 2013. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-3.1.pdf.
20. de Lastours C, Chau F, Roy C, Larroque B, Fantin B. 2014. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother 69:3393-3400. http://dx.doi.org/10.1093/jac/dku283.
21. Hooper DC. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7:337-341. http://dx.doi.org/10.3201/eid0702.010239.
22. Jacoby GA. 2005. Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2):S120-S126. http://dx.doi.org/10.1086/428052.
23. Moon DC, Seol SY, Gurung M, Jin JS, Choi CH, Kim J, Lee YC, Cho DT, Lee JC. 2010. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates. Int J Antimicrob Agents 35:76-79. http://dx.doi.org/10.1016/j.ijantimicag.2009.08.003.
24. Goldstein E, Kirkcaldy RD, Reshef D, Berman S, Weinstock H, Sabeti P, Del Rio C, Hall G, Hook EW, Lipsitch M. 2012. Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States. Emerg Infect Dis 18:1290-1297. http://dx.doi.org/10.3201/eid1808.111202.
25. Biedenbach DJ, Jones RN. 2000. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial surveillance proGram (North and Latin America). Diagn Microbiol Infect Dis 36:255-259. http://dx.doi.org/10.1016/S0732-8893 (00) 00110-3.
26. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. 2006. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis 55:119-127. http://dx.doi.org/10.1016/j.diagmicrobio.2005.12.006.
27. Kawamura Y, Fujiwara H, Mishima N, Tanaka Y, Tanimoto A, Ikawa S, Youko I, Ezaki T. 2003. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother 47:3605-3609. http://dx.doi.org/10.1128/AAC.47.11.3605-3609.2003.
28. Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JF, Huang W, Lauderdale TL. 2014. Levofloxacin-resistant Haemophilus influenzae, Taiwan, 2004-2010. Emerg Infect Dis 20:1386-1390. http://dx.doi.org/10.3201/eid2008.140341.
29. Pletz MW, McGee L, Van Beneden CA, Petit S, Bardsley M, Barlow M, Klugman KP. 2006. Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer. Antimicrob Agents Chemother 50:943-948. http://dx.doi.org/10.1128/AAC.50.3.943-948.2006.
30. Rodríguez-Avial I, Ramos B, Ríos E, Cercenado E, Ordobás M, Sanz JC, Madrid Streptococcus pneumoniae Microbiological Group. 2011. Clonal spread oflevofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009. Antimicrob Agents Chemother 55:2469-2471. http://dx.doi.org/10.1128/AAC.01380-10.
31. Van Heirstraeten L, Leten G, Lammens C, Goossens H, Malhotra-Kumar S. 2012. Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10. J Antimicrob Chemother 67:2602-2605. http://dx.doi.org/10.1093/jac/dks281.